Wanted to open a frank discussion about PT-141 (bremelanotide) since it occupies an interesting niche in the peptide world. It's one of the few peptides that actually made it through FDA approval (as Vyleesi in 2019) for hypoactive sexual desire disorder in premenopausal women. I've been using it off-label for about 6 months and want to discuss mechanism, dosing, and my experience. Particularly relevant for this community because several GLP-1 users report changes in libido — both positive and negative. Mechanism: PT-141 is a melanocortin receptor agonist, primarily targeting MC4R in the central nervous system. Unlike PDE5 inhibitors (Viagra, Cialis) which work peripherally on blood flow, PT-141 acts centrally on hypothalamic pathways that regulate sexual arousal. It's derived from Melanotan II but was developed specifically to isolate the sexual function effects from the tanning effects. The MC4R pathway is fascinating because it intersects with several systems we care about in this community: appetite regulation, energy homeostasis, and metabolic function. In fact, MC4R is one of the key downstream targets of the leptin-melanocortin pathway — the same pathway that GLP-1 RAs interact with indirectly. My protocol (male, off-label use): - Dose: 1.5mg subQ, taken 45-60 minutes before anticipated activity - Frequency: 1-2x per week max (tolerance develops with more frequent use) - Not used daily — this is an as-needed peptide Effects: Noticeable increase in arousal and desire starting around 30-45 minutes post-injection. Duration of effect approximately 6-12 hours. Significantly more prominent "spontaneous" arousal during that window. Side effects: Nausea in the first 30 minutes (dose-dependent — less at 1mg, more at 2mg+), mild facial flushing, transient blood pressure increase (~5-10 mmHg systolic).